Recent advances in immunotherapy for lung cancer
Authors:
Open Access
- 24 February 2023
- journal article
- review article
- Published by Wiley in Cancer Innovation
- Vol. 2 (1) , 18-24
Abstract
Lung cancer is the malignant tumor with the highest morbidity and mortality in China, and nonsmall cell lung cancer is a common form of lung cancer. After undergoing chemotherapy and molecular targeted therapy, the treatment of lung cancer has now fully entered the era of immunotherapy. Immunotherapy‐based treatment has become one of the standard treatments for lung cancer. Immunotherapy has also gradually moved from the back line to the front line, from advanced to early patients. This article focuses on the latest developments in perioperative and advanced lung cancer immunotherapy, discusses the problems and challenges at the current stage, and explores new directions for future development.Keywords
This publication has 28 references indexed in Scilit:
- Patient-reported outcomes with first-line durvalumab plus platinum-etoposide versus platinum-etoposide in extensive-stage small-cell lung cancer (CASPIAN): a randomized, controlled, open-label, phase III studyLung Cancer, 2020
- A Randomized, Placebo-Controlled Trial of Pembrolizumab Plus Chemotherapy in Patients With Metastatic Squamous NSCLC: Protocol-Specified Final Analysis of KEYNOTE-407Journal of Thoracic Oncology, 2020
- Pembrolizumab or Placebo Plus Etoposide and Platinum as First-Line Therapy for Extensive-Stage Small-Cell Lung Cancer: Randomized, Double-Blind, Phase III KEYNOTE-604 StudyJournal of Clinical Oncology, 2020
- Development of bispecific antibodies in China: overview and prospectsAntibody Therapeutics, 2020
- Precision Management of Advanced Non–Small Cell Lung CancerAnnual Review of Medicine, 2020
- Positron-Emission Tomographic Imaging of a Fluorine 18–Radiolabeled Poly(ADP-Ribose) Polymerase 1 Inhibitor Monitors the Therapeutic Efficacy of Talazoparib in SCLC Patient–Derived XenograftsJournal of Thoracic Oncology, 2019
- Updated Analysis of KEYNOTE-024: Pembrolizumab Versus Platinum-Based Chemotherapy for Advanced Non–Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score of 50% or GreaterJournal of Clinical Oncology, 2019
- Mechanisms of PARP inhibitor sensitivity and resistanceDNA Repair, 2018
- Nivolumab versus docetaxel in previously treated advanced non-small-cell lung cancer (CheckMate 017 and CheckMate 057): 3-year update and outcomes in patients with liver metastasesAnnals of Oncology, 2018
- Non-Small Cell Lung Cancer: Epidemiology, Risk Factors, Treatment, and SurvivorshipMayo Clinic Proceedings, 2008